Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Trial Profile

A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs TT 701 (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors OPKO Health; Transition Therapeutics
  • Most Recent Events

    • 09 Nov 2018 According to an OPKO Health media release, enrollment in the trial is expected to be completed by the end of this year.
    • 27 Nov 2017 According to an OPKO Health media release, topline results expected before the end of 2018
    • 27 Nov 2017 According to an OPKO Health media release, first patient has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top